Cargando…

Biodegradable MnO(2)-based gene-engineered nanocomposites for chemodynamic therapy and enhanced antitumor immunity

Immune checkpoint blockade (ICB) is emerging as a promising therapeutic approach for clinical treatment against various cancers. However, ICB based monotherapies still suffer from low immune response rate due to the limited and exhausted tumor-infiltrating lymphocytes as well as tumor immunosuppress...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yiru, Wu, Ming, Wang, Xiaorong, Wang, Peiyuan, Ning, Zhaoyu, Zeng, Yongyi, Liu, Xiaolong, Sun, Haiyan, Zheng, Aixian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812708/
https://www.ncbi.nlm.nih.gov/pubmed/36619204
http://dx.doi.org/10.1016/j.mtbio.2022.100531
Descripción
Sumario:Immune checkpoint blockade (ICB) is emerging as a promising therapeutic approach for clinical treatment against various cancers. However, ICB based monotherapies still suffer from low immune response rate due to the limited and exhausted tumor-infiltrating lymphocytes as well as tumor immunosuppressive microenvironment. In this work, the cell membrane with surface displaying PD-1 proteins (PD1-CM) was prepared for immune checkpoint blockade, which was further combined with multifunctional and biodegradable MnO(2) for systematic and robust antitumor therapy. The MnO(2)-based gene-engineered nanocomposites can catalyze the decomposition of abundant H(2)O(2) in TME to generate O(2), which can promote the intratumoral infiltration of T cells, and thus improve the effect of immune checkpoint blockade by PD-1 proteins on PD1-CM. Furthermore, MnO(2) in the nanocomposites can be completely degraded into Mn(2+), which can catalyze the generation of highly toxic hydroxyl radicals for chemodynamic therapy, thereby further enhancing the therapeutic effect. In addition, the prepared nanocomposites possess the advantages of low cost, easy preparation and good biocompatibility, which are expected to become promising agents for combination immunotherapy.